Chinese Vaccine Manufacturer CanSinoBIO’s Inhaled COVID-19 Vaccine Receives Emergency Use Approval in China

Share this:

Chinese vaccine manufacturer CanSino Biologics Inc. announced on Sunday that China’s drug regulator had given the green light for emergency use of the company’s newly developed inhaled COVID-19 vaccine as a booster.

Does this mean they might be used to “vaccinate” people without their knowledge or permission if they were sprayed into the air?

“CanSino Biologics Inc. (“CanSinoBIO”) announced that the National Medical Products Administration of China (“NMPA”) has granted the Company approval for its Recombinant COVID-19 Vaccine for Inhalation (trade name: Convidecia Air) to be used as a booster dose,” the company said in a news release.

“Utilizing the same adenovirus vector technological platform as the intramuscular version Convidecia, Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air™ is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath,” according to the statement.

The National Medical Products Administration approved CanSino’s version of the adenovirus-vectored COVID-19 vaccine that will potentially benefit its business, according to Channel News Asia citing the company’s filing.

“The approval will have a positive impact on the company’s performance if the vaccine is subsequently purchased and used by relevant government agencies,” CanSino said.

“CanSinoBIO received the approval of its clinical trial application for Convidecia Air in March 2021. Studies published in The Lancet indicated that Convidecia Air™ can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus,” according to the news release.

COVID-19 outbreaks have been on the rise in China recently, according to reports.

China has imposed a lockdown in the city of Chengdu, the capital of the southwestern province of Sichuan, which is home to 21 million people, in order to conduct PCR testing among residents on September 1 as zero-Covid policy continues.

Expectation:

Reality:

Even animals including seafood, and ducks.

Source: Chinese Vaccine Manufacturer CanSinoBIO’s Inhaled COVID-19 Vaccine Receives Emergency Use Approval in China


 


Share this:
Scroll to Top